Inmune Bio, Inc. (INMB)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$1.18-11.65%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · INMB
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 44.1% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 65 industry peers · Company calendar date is not available
INMB — debt issuance
Dated 2026-10-29
Entry into a Material Definitive Agreement. Securities Purchase Agreement On October 27, 2026, INmune Bio Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with a single investor (the “Purchaser”), pursuant to which the Company agreed to issue and sell to the Purchaser, in a registered direct offering (the “Registered Direct Offering”), 3,000,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at…
Why it matters: A filed application would move Ebstrocel closer to review. A delay would weaken the stated filing path.
Supportive ifINmune Bio files the Ebstrocel MAA with the UK MHRA in Q1 2027.
Worry ifThe company reports that the UK MHRA filing was delayed or did not occur by March 31, 2027.
Why it matters: The company agreed to file within 30 days of the offering close. A missed deadline would break that stated step.
Worry ifA resale registration statement covering the offering shares is filed with the SEC by Nov. 28, 2026.
Less concerning ifNo resale registration statement is filed by Nov. 28, 2026, or the company reports a delay.
Why it matters: A trial start would turn the stated Alzheimer’s program into a registered study. A delay would leave progress unclear.
Supportive ifThe company says patient enrollment has started in the integrated Phase 2b/3 XPro1595 trial.
Worry ifThe company reports a delay, a pause, or no trial start in its next program update.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$308 on $10,000 · ±3.1% | How much price usually moves either way. |
| Bad day | $710 loss on $10,000 · 7.1% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,978 loss on $10,000 · 49.8% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.